Clinical trial
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With…
NCT00278213 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00278213 |
|---|---|
| Title | Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia |
| Official title | Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia |
| Lead sponsor | German CLL Study Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prolymphocytic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | alemtuzumab, cyclophosphamide, fludarabine phosphate, mitoxantrone hydrochloride |
| Enrollment | 17 |
| Start date | Sep 1, 2002 |
| Primary completion | Feb 1, 2007 |
| Completion | Dec 1, 2009 |
| First posted | Jan 18, 2006 |
| Last update posted | May 11, 2018 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: